Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cis-trans proline isomers in the catalytic domain of calcineurin

  • Teixeira, João M. C.
  • Guasch, Alicia
  • Biçer, Atilla
  • Aranguren-Ibáñez, Álvaro
  • Chashmniam, Saeed
  • Paniagua, Juan Carlos
  • Pérez‐Riba, Mercè
  • Fita, Ignacio
  • Pons, Miquel
Calcineurin is an essential calcium‐activated serine/threonine phosphatase. The six NMR‐observable methionine methyl groups in the catalytic domain of human calcineurin Aα (CNA) were assigned and used as reporters of the presence of potential cis‐trans isomers in solution. Proline 84 is found in the cis conformation in most calcineurin X‐ray structures, and proline 309, which is part of a highly conserved motif in phosphoprotein phosphatases, was modeled with a cis peptide bond in one of the two molecules present in the asymmetric unit of CNA. We mutated each of the two prolines to alanine to force the trans conformation. Solution NMR shows that the P84A CNA mutant exists in two forms, compatible with cis‐trans isomers, while the P309A mutant is predominantly in the trans conformation., The work was partially supported by funds from the Spanish Ministry of Economy, Industry, and Competitiveness (MINECO) (BIO2016‐78006R, to MP; BFU2015‐71092‐P to IF; SAF2015‐66365 and RTC‐2015‐3386‐1, to MP‐R; Units of Excellence María de Maeztu awards to IF (MDM‐2014‐0435) and to JCP (MDM‐2017–076). Some of the funds were cofinanced with the European Fund for Regional Development (FEDER). We acknowledge additional support from Generalitat de Catalunya (2014‐SGR‐541 and 2017‐SGR‐191). A.B. was funded by the RTC‐2015‐3381‐1 grant. S.C. was a recipient of a short‐term fellowship from the Iranian Government.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Design and synthesis of a novel non peptide CN-NFATc signaling inhibitor for tumor suppression in triple negative breast cancer

  • Sánchez-Morales, Adrià|||0000-0002-8692-0988
  • Biçer, Atilla
  • Panagiotopoulos, Vasilis
  • Crecente-Garcia, Selma|||0000-0001-7572-4458
  • Benaiges Miñarro, Cristina
  • Bayod, Sergi
  • Hernández, José Luís
  • Busqué, Félix|||0000-0001-7566-4264
  • Matsoukas, Minos-Timotheos|||0000-0002-4642-8163
  • Pérez-Riba, Mercè
  • Alibés, Ramon|||0000-0002-7997-2691
The Ca2/calmodulin-mediated phosphatase activity of calcineurin (CN) integrates calcium-mediated signaling with gene expression programs involved in the control of essential cellular processes in health and disease, such as the immune response and the pathogenesis of cancer progression and metastasis. In addition, CN is the target of the immunosuppressive drugs cyclosporine A (CsA) and FK-506 which are the cornerstone of immunosuppressant therapy. Unfortunately, long-term administration of these drugs results in severe side effects. Herein, we describe the design, synthesis and evaluation of new synthetic compounds that are capable of inhibiting NFATc activity in a dose-dependent manner, without interfering on CN phosphatase activity. These compounds were designed using the structure-based pharmacophore model of a peptide-derived PxIxIT sequence binding to calcineurin A subunit. Moreover, these compounds inhibit NFATc-dependent cytokine gene expression, secretion and proliferation of human T CD4 cells. More importantly, compound 5a reduces tumor weight and shows a tendency to reduce tumor angiogenesis in an orthotopic immunocompetent mouse model of triple negative breast cancer, suggesting that 5a has tumor suppressor activity. These findings validate compound 5a as an agent with therapeutic activity against CN-NFATc and highlight its potential as a tool for drug development with therapeutic purposes.